146136-24-5

Upstream product

• 114371-49-2 ethyl -5-cyclohexyl-4-<<(1,1-dimethylethoxy)carbonyl>amino>-2-pentenoate 
• 98105-42-1 (S)-2-(t-butoxycarbonylamino)-3-cyclohexyl-1-propanal 

Downstream Products

• 130405-85-5 (3S,4S)-3-Benzyloxycarbonylamino-4-tert-butoxycarbonylamino-5-cyclohexyl-pentanoic acid ethyl ester 
• 130405-86-6 (3R,4S)-3-Benzyloxycarbonylamino-4-tert-butoxycarbonylamino-5-cyclohexyl-pentanoic acid ethyl ester 
• 1057661-66-1 (S)-3,4-Diamino-5-cyclohexyl-pentanoic acid ethyl ester 
• 130405-96-8 (3R,4S)-3-Amino-5-cyclohexyl-4-[(S)-2-(8-isobutyl-6-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-3-pyridin-3-yl-propionylamino]-pentanoic acid {(S)-3-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butyl}-amide 
• 130405-96-8 N₄-<(2S)-2-(8-Isobutyl-6-phenyl-1,2,4-triazolo<4,3-a>pyrazin-3-yl)-3-pyridin-3-ylpropanoyl>-(S)-CDAPA-Leu pyridin-2-ylmethylamide 
• 130405-96-8 (3R,4S)-3-Amino-5-cyclohexyl-4-[(R)-2-(8-isobutyl-6-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-3-pyridin-3-yl-propionylamino]-pentanoic acid {(S)-3-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butyl}-amide 
• 130405-96-8 N₄-<(2R)-2-(8-isobutyl-6-phenyl-1,2,4-triazolo<4,3-a>pyrazin-3-yl)-3-pyridin-3-ylpropanoyl>-(S)-CDAPA-Leu pyridin-2-ylmethylamide 
• 130405-91-3 N₃-Z-N₄-<(2RS)-2-(8-isobutyl-6-phenyl-1,2,4-triazolo<4,3-a>pyrazin-3-yl)-3-pyridin-3-ylpropanoyl>-(S)-CDAPA-Leu pyridin-2-ylmethylamide 
• 130405-88-8 N₃-Z-(3R,4S)-5-cyclohexyl-3,4-diaminopentanoic acid γ-lactam 
• 130405-87-7 N₃-Z-(3S,4S)-5-cyclohexyl-3,4-diaminopentanoic acid γ-lactam 
• 130405-89-9 N₃-Z-N₄-Boc-(3S,4S)-5-cyclohexyl-3,4-diaminopentanoic acid 
• 130405-89-9 N₃-Z-N₄-Boc-(3R,4S)-5-cyclohexyl-3,4-diaminopentanoic acid 
• 130405-90-2 [(1R,2S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-1-({(S)-3-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butylcarbamoyl}-methyl)-propyl]-carbamic acid benzyl ester 
• 130405-90-2 N₃-Z-N₄-Boc-(S)-CDAPA-Leu pyridin-2-ylmethylamide 

Relevant academic research and scientific papers

1,2,4-Triazolopyrazine Derivatives with Human Renin Inhibitory Activity. 3. Synthesis and Biological Properties of Aminodeoxystatine and Difluorostatone Derivatives

Two series of 1,2,4-triazolopyrazine derivatives with human renin inhibitory activity have been synthesized which incorporate the transition-state mimetics (3S,4S)- and (3R,4S)-5-cyclohexyl-3,4-diaminopentanoic acid ((S)- and (R)-CDAPA), and (4S)-4